ROIV FDA approval of LISRAYA for dermatomyositis; launches immediately
ROIV says the FDA approved LISRAYA as the first oral targeted therapy for dermatomyositis, with launch immediately.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.